Previous 10 | Next 10 |
WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participa...
2024-05-08 12:32:09 ET Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Conference Call May 08, 2024 8:00 AM ET Company Participants Bennett Watson – ICR Westwicke Investor Relations Dan Barber – Chief Executive Officer and President Ernie Toth ...
2024-05-07 17:27:26 ET Aquestive Therapeutics press release ( NASDAQ: AQST ): Q1 GAAP EPS of -$0.17. Revenue of $12.05M (+8.3% Y/Y). Aquestive's full-year 2024 financial guidance is below.... The Company expects: Read the full article on Seeking Alpha ...
Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen ® and other injectors used for the treatment of anaphylaxis On track to complete Anaphylm temperature/pH study in second quarter 2024 Receiv...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
2024-04-29 13:56:26 ET More on Aquestive Therapeutics Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings ...
2024-04-29 10:02:54 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5 Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of age Company track r...
2024-04-27 08:09:56 ET More on Aquestive Therapeutics Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings ...
WARREN, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pH Remains on track to complete Anaphylm supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024 Continues to anticipate filin...
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...